Relapsed/refractory B-cell non-Hodgkin lymphoma research hub

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma

This study is testing a new treatment called GLPG5101 for a type of blood cancer called B-cell non-Hodgkin lymphoma. It's for people whose cancer has come back or hasn't responded to other treatments. Researchers want to see if the treatment is safe and effective.